v3.26.3
COLLABORATION AND LICENSE AGREEMENTS (Details)
$ in Thousands
1 Months Ended 3 Months Ended 4 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2026
USD ($)
Jan. 31, 2024
USD ($)
performance_obligation
Sep. 30, 2021
USD ($)
performance_obligation
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue       $ 224,563 $ 164,859   $ 521,345 $ 361,039  
License and collaboration revenue                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue       4,367 51,709   15,305 77,187  
Collaborative Arrangement | Vifor Pharma                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment     $ 55,000            
Milestone payments (up to)     $ 845,000            
Percentage of royalty on net sales receives     40.00%            
Force majeure event period threshold     6 months            
Revenue     $ 55,000            
Number of performance obligations | performance_obligation     2            
Deferred revenue     $ 43,000            
Collaborative Arrangement | Vifor Pharma | Regulatory and Market Access Milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone payments (up to)     135,000            
Collaborative Arrangement | Vifor Pharma | Sales-based Milestone Payments                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone payments (up to)     $ 655,000            
Collaborative Arrangement | Vifor Pharma | License and collaboration revenue                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue       4,100 42,400 $ 12,000 10,000 67,900  
Collaborative Arrangement | Vifor Pharma | Market Access Milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue         40,000     57,500  
Collaborative Arrangement | Vifor Pharma | Regulatory Milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue               17,500  
Collaborative Arrangement | Chugai                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Force majeure event period threshold   9 months              
Revenue   $ 8,300              
Number of performance obligations | performance_obligation   1              
Collaborative Arrangement | Chugai | License and collaboration revenue                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue                 $ 9,300
Milestone payment from collaborator, recognized       300 $ 9,300   5,300 $ 9,300  
Collaborative Arrangement | Chugai | Regulatory Milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone payment from collaborator, recognized       $ 5,000     5,000    
Collaborative Arrangement | Chugai | Regulatory Development and Sales Based Milestone                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone payments (up to)   $ 120,000              
Collaborative Arrangement | PTE. Ltd. | License and collaboration revenue                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment $ 112,500                
Milestone payments (up to) $ 1,000,000                
Asset acquisition, consideration transferred             $ 113,100